Cizzle Biotechnology never a better time to invest in diagnostics (Interview)

Cizzle Biotechnology Holdings plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk to discuss the successful listing on to the Main Market of London Stock Exchange. Allan explains what the company does, how a blood test for the early detection of a majority of the different forms of lung cancer works, patents in place, how the proceeds will be utilised and how Allan views the outlook for the company.

Cizzle Biotechnology is a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer.

You might also enjoy reading  Cizzle Biotechnology update on development of proprietary antibodies

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
Cizzle Biotechnology
Cizzle Biotechnology never a better time to invest in diagnostics (Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions